- Supported exchanges /
- F /
- 6XC.F
SOLENO THERAPEUT. DL-001 (6XC F) stock market data APIs
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
SOLENO THERAPEUT. DL-001 Financial Data Overview
| 50.8 | |
| 51.05 | |
| - | |
| 51.05 | |
| 49.68 | |
| 20.1-51.35 | |
| 1 945 M | |
| 38 872 K | |
| 0 | |
| -1.448 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
SOLENO THERAPEUT. DL-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -66 532 000
- Earnings Per Share -1.69
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get SOLENO THERAPEUT. DL-001 Earnings via APIs
- Latest Release 2024-11-05
- EPS/Forecast NaN
Get SOLENO THERAPEUT. DL-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
